Ascendis Pharma A/S (ASND) Projected to Post Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) is projected to release its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect Ascendis Pharma A/S to post earnings of $0.13 per share and revenue of $285.3480 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $250.71 million during the quarter, compared to analysts’ expectations of $246.91 million. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $222.03 on Tuesday. Ascendis Pharma A/S has a 12 month low of $118.03 and a 12 month high of $242.00. The company has a fifty day moving average price of $213.59 and a two-hundred day moving average price of $203.87. The company has a market cap of $13.76 billion, a PE ratio of -50.01 and a beta of 0.44.

Analyst Ratings Changes

Several research analysts have recently commented on ASND shares. Stifel Nicolaus lifted their price target on shares of Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Raymond James Financial started coverage on Ascendis Pharma A/S in a research note on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Finally, Royal Bank Of Canada raised their price target on Ascendis Pharma A/S from $245.00 to $250.00 and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and a consensus price target of $270.76.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at approximately $26,000. Global Retirement Partners LLC boosted its position in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares during the period. Quadrant Capital Group LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth $74,000. Certuity LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter valued at $220,000. Finally, PharVision Advisers LLC bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at about $233,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.